Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698270 | 0.91 | NPC1 (0.50) | ALDH1A1SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL19698367 | 0.87 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL20034767 | 0.86 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL19698416 | 0.86 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CYP2D6KCNH2HRH3 | |
| SCHEMBL30713417 | 0.80 | CYP2D6 (0.46) | ALDH1A1CYP2D6KCNH2HRH3NPC1 | |
| SCHEMBL24701188 | 0.78 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19975948 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2HRH3LMNAEPHX2 | |
| SCHEMBL11960551 | 0.77 | CYP2D6 (0.46) | ALDH1A1CYP2D6KCNH2HRH3NPC1 | |
| SCHEMBL12793198 | 0.77 | CYP2D6 (0.46) | ALDH1A1CYP2D6KCNH2HRH3NPC1 | |
| SCHEMBL20035024 | 0.76 | LMNA (0.66) | SMN1; SMN2CYP2D6KCNH2HRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885SMN1; SMN2 2500/4885CYP2D6 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.